AV-001 Injection i Lungebetændelse, viral og Lungebetændelse og Acute respiratory distress syndrom - Kliniske forsøgsregister

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Pneumonia is a leading cause of hospitalization among adults and children in the United States and has ranked among the top 10 causes of death according to the CDC. A large variety of microorganisms can cause pneumonia including respiratory viruses, bacteria and fungi and there are great geographic variations in their prevalence. In the United States, common causes of viral pneumonia are SARS-CoV-2, influenza and respiratory syncytial virus (RSV) and bacterial pneumonia are Streptococcus pneumoniae (pneumococcus).

Emerging evidence indicates that the respiratory system mechanics of patients with typical ARDS, with or without COVID-19 are broadly similar in contrast to earlier reports that suggested COVID-19-associated ARDS has distinctive features. SOC for patients with ARDS remains limited with current interventions that focus primarily on supportive therapy, including fluid management strategies and further injury prevention via lung protective ventilation. Ventilation approaches remain the cornerstone in the treatment of ARDS and approaches to minimize ventilator-induced lung injury (VILI) resulting from the imposition of stretch-trauma to the lung, continue to be a major focus of clinical importance. Several techniques may be utilized to accomplish this objective. Clinical guidelines strongly recommend volume-limited or pressure-limited ventilator approaches for patients with severe ARDS and high positive-end expiratory pressure strategies for patients with moderate to severe ARDS. Despite decades of improving supportive care, mortality remains high, ranging from 34.9% of patients with mild ARDS to 46.1% of patients with severe ARDS.

Whatever the causative organism it is increasingly apparent that their impact on lung microvasculature is a major contributing factor to morbidity and mortality associated with those infections. Most deaths from influenza virus infections occur due to pulmonary complications, in particular the development of acute respiratory distress syndrome (ARDS), that is due to increased permeability of the lung microvasculature. Emerging evidence in COVID-19 infections suggest a similar pathophysiology where pulmonary endothelial cells and vascular dysfunction contribute to the initiation and propagation of ARDS by altering blood vessel integrity, promoting a pro-coagulative state, inducing endotheliitis and mediating inflammatory cell infiltration. Therefore, a therapeutic intervention that could modulate the course of pulmonary disease not by treating the causative organism but by reducing the deleterious inflammatory sequalae of those infections may have a significant positive impact

AV-001 is a synthetic Angiopoietin-1 (Angpt-1) mimetic that has been shown to activate the Tie2 receptor tyrosine kinase; a transmembrane protein target most highly expressed on the surface of endothelial cells in the vasculature. The Tie2/Angiopoietin signaling axis has been identified as a nonredundant gatekeeper of vascular homeostasis. In healthy individuals, Tie2 is highly activated and signals the endothelium to fortify intracellular junctions and reduce expression of adhesion molecules, which serve as leukocyte tethers upon inflammation. As such, homeostatic activation results in the promotion of barrier defense against vascular leakage.

A total of 60 eligible patients (20 patients each in cohorts 1, 2 and 3) will be recruited from participating institutions / hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with SOC. All patients will receive supportive care according to the SOC for the trial site hospital likely to include remdesivir and or dexamethasone. Study drug will be administered by bolus IV injection (< 60 seconds). Doses of AV-001 Injection to be administered will start with the lowest proposed dose of 12.5 μg/kg/day in cohort 1 (DL1) and are anticipated to increase to 25μg/kg/day in cohort 2 (DL2), 56 μg/kg/day in cohort 3 (DL3).

The study population for this Phase 2a study will consist of male and non-pregnant female patients, ≥ 18 years of age, hospitalized with presumed pneumonia secondary to SARS-CoV-2 or other viral or bacterial infection with acute onset to a respiratory compromise requiring supplemental oxygen therapy.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

60

Fase

Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Forenede Stater
- California
  - Newport Beach, California, Forenede Stater, 92658-6100
    - Hoag Memorial Hospital Presbyterian
- Colorado
  - Denver, Colorado, Forenede Stater, 80203
    - Denver Health Medical Center
- Illinois
  - Chicago, Illinois, Forenede Stater, 60611
    - Northwestern University Medical Center
- Maryland
  - Hyattsville, Maryland, Forenede Stater, 20782
    - MedStar Health Research Institute, Inc.
- Michigan
  - Detroit, Michigan, Forenede Stater, 48202
    - Henry Ford Health System
- Ohio
  - Columbus, Ohio, Forenede Stater, 43210
    - The Ohio State University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Able and willing to give signed informed consent
Patients hospitalized with a presumed diagnosis of pneumonia of < 48 hours duration requiring supplemental oxygen therapy. Eligible patients include those hospitalized for a separate non-infectious reason who subsequently develop a presumed pneumonia;
Radiologic imaging (chest x-ray, CT scan, etc.) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation.

Signs and symptoms:

At least 1 of the following signs:

respiratory rate > 30 breaths/min;
fever (> 38.0ºC or > 100.4o F);
leukopenia (≤ 4,000 WBC/mm3 or leukocytosis (≥ 12,000 WBC/mm3);
adults ≥ 70 years of age; altered mental status with no other recognized cause;

AND at least 1 of the following symptoms:

New onset of purulent sputum or change in character of sputum or increased respiratory secretions;
New onset or worsening cough, or dyspnea, or tachypnea;
Rales or bronchial breath sounds;
- Female patients of reproductive potential must be on an effective contraceptive method

Exclusion Criteria:

Pregnant and/or lactating women
Patients included in any other interventional trial
Use of endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at screening
Any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to:
- Septic shock as defined by systolic blood pressure (SBP) < 90 mmHg or diastolic blood pressure (DBP) of < 60 mmHg;
- Multiple organ failure;
- Are moribund irrespective of the provision of treatments;
- Any significant bleeding disorder or vasculitis;
- Any serious, nonhealing wound, peptic ulcer or bone fracture;
- Liver cirrhosis;
- History of a hypertensive crisis or hypertensive encephalopathy, or current, poorly controlled hypertension or hypotension;
- Severe renal insufficiency or end stage renal disease as determined by estimated glomerular filtration rate <30mL/min/1.73m2;
- ARDS risk factors of aspiration pneumonia, non-cardiac shock, trauma, blood transfusion or drug overdose.
Any thromboembolic event within the past 3 months;
Symptomatic congestive heart failure or symptomatic or poorly controlled cardiac arrhythmia > class II as per New York Heart Association (NYHA) classification;
History of autonomic disorders or uncontrolled hypotension
Hypersensitivity to drug products containing polyethylene glycol (PEG)
Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Primært formål: Behandling
Tildeling: Randomiseret
Interventionel model: Sekventiel tildeling
Maskning: Firedobbelt

Antal våben

2

Våben og indgreb

Deltagergruppe / Arm	Intervention / Behandling
Aktiv komparator: AV-001 Injection with standard of care (SOC). A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3.	Medicin: AV-001 Injection AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
Placebo komparator: AV-001 Placebo Injection with standard of care (SOC). A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).	Medicin: AV-001 Placebo Injection D-PBS

Deltagergruppe / Arm

Intervention / Behandling

Aktiv komparator: AV-001 Injection with standard of care (SOC).

A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3.

Medicin: AV-001 Injection

AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

Placebo komparator: AV-001 Placebo Injection with standard of care (SOC).

A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

Medicin: AV-001 Placebo Injection

D-PBS

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål	Foranstaltningsbeskrivelse	Tidsramme
Safety and tolerability of multiple doses of IV administrations of AV-001 Injection compared with AV-001 placebo Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 60	Number of patients with any serious adverse event (SAE) (day 1 to 60/EOS) Number of patients with any treatment emergent adverse event (TEAE) (day 1 to 60/EOS) AE assessments (day 1 to 60/EOS)	Up to Day 60

Sekundære resultatmål

Resultatmål	Foranstaltningsbeskrivelse	Tidsramme
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as proportion of patients achieving a 2-point improvement in WHO COVID-19 CPS score from baseline and alive by day 28.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Time to first 2-point WHO CPS improvement using a Kaplan-Meier lifetable	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as survival at day 28, displayed with a Kaplan- Meier lifetable.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as proportion of patients that progress to respiratory failure by day 28.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as proportion of patients that progress to mechanical ventilation by day 28.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as proportion of patients with disease improvement of at least 1 point on the WHO COVID-19 CPS for 3 consecutive days and sustained the improvement through day 28.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	SpO2 saturation (up to day 28): measured as proportion of patients achieving normalization (last oxygen saturation of arterial blood [SaO2] value > 95%).	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Oxygen delivery: measured as the product of flow rate and volume per day.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Measured as the acute kidney injury stage distribution over time using the Kidney Disease Improving Global Outcomes (KDIGO) definition of Acute Kidney Injury (AKI).	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as proportion of patients alive and discharged from the intensive care unit (ICU) at day 28.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as proportion of patients alive and discharged from hospital at day 28.	Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 28	Measured as time to hospital discharge status (discharge or day 28, whichever is earlier).	Up to Day 28

Andre resultatmål

Resultatmål	Foranstaltningsbeskrivelse	Tidsramme
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 60	Measured as alive at day 60, displayed with a Kaplan- Meier lifetable.	Up to Day 60
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 14	Measured as proportion of patients that progress to respiratory failure by day 14.	Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 14	Measured as proportion of patients that progress to mechanical ventilation by day 14.	Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 14	Proportion of patients achieving a 2-point improvement in WHO COVID-19 CPS score from baseline and alive by day 14.	Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 14	Measured as proportion of patients alive and discharged from the intensive care unit (ICU) at day 14.	Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 14	Measured as proportion of patients alive and discharged from hospital at day 14.	Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections Tidsramme: Up to Day 60	Measured as durable loss of eGFR (by day 28 and day 60) from baseline (89-60 mL/min, 59-45 mL/min, 30-44 mL/min, <30 mL/min) or the development of severe AKI requiring continuous renal replacement therapy (CRRT), prolonged intermittent renal replacement therapy (PIRRT) or hemodialysis.	Up to Day 60
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on exploratory biomarkers of Tie2 target engagement Tidsramme: Up to Day 28	Measured as ratio of phosphorylated Tie2/Total Tie2 using flow cytometry analysis.	Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on exploratory biomarkers (Angpt-1, Angpt-2, and circulating Tie2). Tidsramme: Up to Day 28	Measured using quantitative ELISA.	Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarkers IL-6 in patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.	Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker IL-8 in patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.	Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarkers TNFr-1 in patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.	Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker MCP-1 in patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.	Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker IP-10 in patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.	Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker ICAM-1, in in patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.	Up to Day 28
PK as measured by Cmax of AV-001 Injection in hospitalized patients with severe COVID-19 disease. Tidsramme: Up to Day 28	Assessment of the PK of AV-001 Injection in hospitalized patients with severe COVID-19 disease using population PK for DL1, DL2 and DL3. PK measured as Cmax from sample timepoints Pre-dose, 5 min, 30 min, 1, 2, 4, and 24 hours post-dose on days 1, 7 and the earlier of day 28 or EOT.	Up to Day 28
PK as measured by Tmax of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Assessment of the PK of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections using population PK for DL1, DL2 and DL3. PK measured as Tmax, from sample timepoints Pre-dose, 5 min, 30 min, 1, 2, 4, and 24 hours post-dose on days 1, 7 and the earlier of day 28 or EOT.	Up to Day 28
PK as measured by AUC of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections. Tidsramme: Up to Day 28	Assessment of the PK of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections using population PK for DL1, DL2 and DL3. PK measured as AUC from sample timepoints Pre-dose, 5 min, 30 min, 1, 2, 4, and 24 hours post-dose on days 1, 7 and the earlier of day 28 or EOT.	Up to Day 28

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Vasomune Therapeutics, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. december 2021

Primær færdiggørelse (Anslået)

1. september 2026

Studieafslutning (Anslået)

1. september 2026

Datoer for studieregistrering

Først indsendt

8. november 2021

Først indsendt, der opfyldte QC-kriterier

15. november 2021

Først opslået (Faktiske)

17. november 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

AV001-004
CDMRP-PR203503 (Andet bevillings-/finansieringsnummer: CDMRP)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Fase 2a Multiple Ascending Dose Studie i hospitalsindlagte patienter med lungebetændelse.

Et randomiseret, dobbeltblindt, placebokontrolleret, fase 2a-studie med flere stigende doser for at undersøge sikkerheden, tolerabiliteten og effektiviteten af ​​AV-001-injektion hos patienter indlagt med lungebetændelse på grund af COVID-19 eller andre luftvejsinfektioner.

Studieoversigt

Status

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Undersøgelsestype

Tilmelding (Faktiske)

Fase

Kontakter og lokationer

Studiesteder

Deltagelseskriterier

Berettigelseskriterier

Aldre berettiget til at studere

Tager imod sunde frivillige

Køn, der er berettiget til at studere

Beskrivelse

Studieplan

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Antal våben

Våben og indgreb

Deltagergruppe / Arm

Intervention / Behandling

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål

Foranstaltningsbeskrivelse

Tidsramme

Sekundære resultatmål

Resultatmål

Foranstaltningsbeskrivelse

Tidsramme

Andre resultatmål

Resultatmål

Foranstaltningsbeskrivelse

Tidsramme

Samarbejdspartnere og efterforskere

Sponsor

Datoer for undersøgelser

Studer store datoer

Studiestart (Faktiske)

Primær færdiggørelse (Anslået)

Studieafslutning (Anslået)

Datoer for studieregistrering

Først indsendt

Først indsendt, der opfyldte QC-kriterier

Først opslået (Faktiske)

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Sidst verificeret

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Studerer et amerikansk FDA-reguleret enhedsprodukt

Et randomiseret, dobbeltblindt, placebokontrolleret, fase 2a-studie med flere stigende doser for at undersøge sikkerheden, tolerabiliteten og effektiviteten af AV-001-injektion hos patienter indlagt med lungebetændelse på grund af COVID-19 eller andre luftvejsinfektioner.